IQVIA (IQV) Q3 Earnings Lift Guidance As Margins Keep Building

IQVIA Holdings came into this Q3 2026 report with its stock near record territory after a 90-day gain of about 9.7%, yet the first day reaction was a modest 0.8% slip to about US$271.55. For a business often framed as a high quality compounder in clinical research and commercial data, that muted move sits awkwardly against a quarter where revenue reached US$4.43b and adjusted diluted earnings per share climbed to US$3.34. The core story was margin power, with adjusted EBITDA hitting US$1.03b and expanding even as life sciences clients pushed hard on execution and timelines.

Love IQVIA Holdings’ earnings strength but want a wider set of high margin, cash generative options to compare it against? Explore peers with similar quality and sturdier balance sheets in the list of solid balance sheet and fundamentals stocks (24 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$4,428m vs. US$4,100m (+8.0%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$350m vs. US$331m (+5.7%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$2.13 vs. US$1.94 (+9.3%)
• Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): approximately 23.2% vs. approximately 23.0% (increase of about 20 bps)

AI is now central to IQVIA’s strongest bookings in years. Ask Charlie what IQVIA’s AI wins signal for future growth.

Evaluating IQVIA’s AI And Backlog Upside Claims

Supporters argue that IQVIA Holdings has an AI and backlog engine that can compound into stronger growth and profitability over time.

"The main requirement is that IQVIA converts its growing R&DS backlog, emerging biopharma mix, and Commercial Solutions pipeline into sustained organic growth, while using AI to support margins despite client insourcing concerns."

Q3 points in that direction. Organic revenue rose about 6%, with R&DS bookings of US$3.2b and a 1.2 book to bill, and last 12 month net new bookings up 14% to US$11.7b. Adjusted EBITDA grew slightly faster than sales, margins ticked higher despite pass through pressure, and management lifted full year revenue, EBITDA and EPS guidance while highlighting AI driven productivity gains.

The price and this Narrative do not agree. → Uncover what this Narrative says IQVIA Holdings is actually worth.

IQVIA Bear Case: Privacy, AI, And Outsourcing Stress Test

Bearish views focus on IQVIA Holdings losing analytics work as clients pull more data science in house and lean on internal AI stacks.

"Although IQVIA Holdings is positioning its AI agents across hundreds of clinical and commercial use cases with most large pharma already engaged, wider client adoption of in house AI tools could still redirect data management and analytics spend away from external providers and compress future revenue and net margin growth if contracts are re scoped or not renewed."

Q3 results do not show that squeeze yet. Organic revenue grew in both segments, AI offerings are cited as win drivers, and margins held near 23.2% despite higher pass throughs. The risk is more about future contract renewals than current numbers.

Hunt For Disconnected Fundamentals

IQVIA Holdings shows how earnings strength and a muted share reaction can sit side by side. The real opportunity could be finding stocks that look mispriced before the market closes that gap.

• Company 1 - 23% below our estimate - sell liquid cooling and power systems as air-based solutions meet physical constraints.
• Company 2 - 42% below our estimate - expand a coconut based drinks category as retailers balance branded and private label offerings.
• Company 3 - 34% below our estimate - advise on mergers, restructurings and capital raises as a senior team converts a strong deal pipeline.

Those are three of them. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com